Efficient Synthesis of HIV-1 Protease Inhibitors
- 總結
- Researchers at Purdue University have developed a new series of hexahydrofuropyran-derived HIV-1 protease inhibitors for treatment of HIV infection and AIDS. These inhibitors are novel and remarkably potent, similar to Darunavir, an FDA approved inhibitor also developed at Purdue. They also show excellent activity against multiple PI-resistant variants, superior to other FDA approved inhibitors.
- 技術優勢
- High antiviral potencyEffective against wide range of variants
- 技術應用
- Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
- 詳細技術說明
- Arun GhoshGhosh GroupPurdue Chemistry
- *Abstract
-
- *Background
- HIV-1 protease inhibitors are critical components of highly active antiretroviral therapy (HAART). The HAART treatment regimens significantly reduced HIV/AIDS-related mortality. However, the rapid emergence of drug-resistant HIV-1 strains and the appearance of cross-resistance are severely limiting long-term treatment options.
- *IP Issue Date
- May 5, 2015
- *IP Type
- Cont-in-Part
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- 國家
- United States
- 申請號碼
- 9,024,038
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
